Countervail Corporation

Home
About Us
Technologies
Investors
Contact Us
News

April 2014

US CIP Patent awarded for use of galantamine as Method of Treating Organophosphorus Poisoning.

April 3, 2014 • admin • General News

Read More »

Search for:

Latest News

Market Analysis Study for Countervail’s Novel Diagnostic Test Technology
New Countervail Corporation Patent Issued by USPTO
Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO

Archives

Countervail Corporation's mission is to provide a layer of protection against the pesticides, chemical agents and other dangerous elements that threaten public safety.

By developing technologies and drugs that serve as counter agents, Countervail leads the way in making our world a better place.

Latest News

Market Analysis Study for Countervail’s Novel Diagnostic Test Technology
New Countervail Corporation Patent Issued by USPTO
Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO

Looking For Something?

Search for:

© 2019 Countervail Corporation • Powered by Red Cape Design